Targeting DNA mismatch repair for radiosensitization

Seminars in Radiation Oncology

Volumn 11, Issue 4, 2001, Pages 300-315

  Berry, Suzanne E ^a   Kinsella, Timothy J ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CARBOPLATIN; CISPLATIN; IDOXURIDINE; METHYLNITROSOUREA; PROCARBAZINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; THIOGUANINE DERIVATIVE; THYMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE MISPAIRING; CANCER RADIOTHERAPY; DNA REPAIR; DNA REPLICATION; HUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT INDICATION;

EID: 0034798687     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/S1053-4296(01)80067-9     Document Type: Article

References (113)

1. Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis
2. The MutL ATPase is required for mismatch repair
3. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis
4. A mutation of the yeast gene encoding PCNA destabilizes both microsatellite and minisatellite DNA sequences
5. DNA polymerase δ is required for human mismatch repair in vitro
6. Identification and characterization of Saccharomyces cerevisiae EXO1, a gene encoding an exonuclease that interacts with MSH2
7. The 3′→5′ exonucleases of DNA polymerases δ and ε and the 5′→3′ exonuclease Exol have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae
8. 4-methylthymine, of the Cisplatin-d(GpG) Adduct
9. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
10. 2-M cell cycle checkpoint arrest following ionizing radiation
11. 2 cell cycle checkpoint
12. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-Methyl-N′-nitro-N-nitrosoguanidine
13. 2/M cell cycle arrest and lethality after DNA damage
14. Involvement of the mismatch repair system in Temozolomide-induced apoptosis
15. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSII2 and MSII6
16. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
17. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line
18. hMLII1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
19. 6-methyl-guanine-DNA methyhransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
20. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
21. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
22. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
23. IlmutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
24. APC mutations in colorectal tumors with mismatch repair deficiency
25. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
26. Transforming growth factor β type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer
27. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
28. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas
29. Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer
30. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype
31. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas
32. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene
33. Germline hMSII2 and differential somatic mutations in patients with Turcot's syndrome
34. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas
35. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation
36. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1
37. Neurofibromatosis and early onset of cancers in hMLH1-deficient children
38. Molecular genetics of neurofibromatosis types 1 and 2
39. cDNA cloning of the type I neurofibromatosis gene: Complete sequence of the NF1 gene product
40. Paternal origin of new mutations in Von Recklinghausen neurofibromatosis
41. An update of IINPCC (Lynch syndrome)
42. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
43. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer
44. Germ-line mutation of the hMSII6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred
45. Germ-line msh6 mutations in colorectal cancer families
46. Incidence and functional consequences of hMLII1 promoter hypermethylation in colorectal carcinoma
47. A role for methylation of the hMLII1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
48. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1
49. Methylation of hMLH1 in a population-based series of endometrial carcinomas
50. MLH1 promoter methylation and gene silencing is the primary, cause of microsatellite instability in sporadic endometrial cancers
51. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix
52. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast
53. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability
54. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea
55. Biochemical correlates of temozolomide sensitivity in pedriatric solid tumor xenograft models
56. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-Methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation
57. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine
58. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses
59. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to Cisplatin in human tumor cells
60. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma
61. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
62. Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival
63. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation
64. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts
65. Apoptosis induced by overexpression of hMSH2 or hMLH1
66. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways
67. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation
68. MSII2 and MSII6 are required for removal of adenine misincorporated opposite 8-oxo-guanine in S. cerevisiae
69. Loss of DNA mismatch repair imparts defective cdc2 signaling and G2 arrest responses without altering survival after ionizing radiation
70. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
71. The role of mismatch repair in the prevention of base pair mutations in Saccaromyces cerevisiae
72. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts
73. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
74. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer
75. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
76. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues
77. Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells
78. Mutagenicity and cytotoxicity of nineteen heterocyclic mustards (ICR compounds) in cultured mammalian cells
79. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor Aphidicolin
80. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo
81. Survival improvement in anplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-19, phase I-II study
82. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vineristine for the treatment of anaplastic gliomas
83. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
84. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver
85. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases
86. Incorporation of 5-Bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion
87. A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer
88. Clinical experience with intravenous radiosensitizers in unresectable sarcomas
89. Preoperative iododeoxyuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up
90. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas
91. An in-vivo comparison of oral 5-Iodo-2′-deoxyuridine and 5-Iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT116
92. Preclinical evaluation of 5-Iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-Iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues
93. Pre-clinical toxicity, pharmacology, and efficacy study of a 14-day schedule of oral 5-Iodo-2′-pyrimidinone-2′-deoxyribose (iPdR) as a prodrug for IudR-radiosensitization in U251 human glioblastoma xenografts
94. Pre-clinical study of the systemic toxicity and pharmacokinetics of 5-Iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a radiosensitizing prodrug in two, non-rodent animal species: Implications for phase I study design
95. Halogen anion formation in 5-IIalouracil films: X rays compared to subionization electrons
96. Mechanism of radiosensitization by halogenated pyrimidines: Effect of BrdUrd on radiation induction of DNA and chromosome damage and its correlation with cell killing
97. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by Iododeoxyuridine
98. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. Radiosensitization of human colon cancer cells by Bromodeoxyuridine
99. Selective radiosensitization of drug-resistant, MSII2 mismatch repair-deficient cells by halogenated thymidine (dThd) analogs; Msh2 mediates dThd analog DNA levels, and the differential cytotoxicity and cell cycle effects of the dThd analogs and 6-TG
100. The mismatch repair protein, hMLII1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells
101. Cooperation between p53 and hMLH1 in a human colorectal carcinoma cell line in response to DNA damage
102. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
103. Radiosensitization by fluorodeoxyuridine effects of thymidylate synthase inhibition and cell synchronization
104. The role of cell cycle redistribution in radiosensitization: Implications regarding the mechanism of fluorodeoxyuridine radiosensitization
105. Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation
106. Comparison of 5-Fluoro-2′-deoxyuridine with 5-Fluorouracil and their role in the treatment of colorectal cancer
107. 1 restriciton point into S-phase: Implications for fluoropyrimidine radiosensitization
108. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation
109. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines
110. Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines
111. Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy
112. Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system
113. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma